PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
6510544-6	1984	In the larger group of 13, a drop in the low density lipoprotein cholesterol (LDL-C) to HDL-C ratio and LDL-C was also seen.	density lipoprotein cholesterol	45-76	component of oligomeric golgi complex 2	Homo sapiens	78-83	
20615262-1	2010	BACKGROUND: To evaluate the relationship between the low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio and HDL subclass distribution and to further examine and discuss the potential impact of LDL-C and HDL-C together with TG on HDL subclass metabolism.	density lipoprotein cholesterol	57-88	component of oligomeric golgi complex 2	Homo sapiens	90-95	
30365923-3	2019	LDL-C is typically calculated using the Friedewald equation: (total cholesterol) - (non-high-density lipoprotein cholesterol [non-HDL-C]) - (triglycerides [TGs]/5).	density lipoprotein cholesterol	93-124	component of oligomeric golgi complex 2	Homo sapiens	0-5	
27471056-1	2016	Low-density lipoprotein cholesterol (LDL-C) only partly represents the atherogenic lipid burden, and a growing body of evidence suggests that non-high-density lipoprotein cholesterol (non-HDL-C), triglycerides, and apolipoprotein B (apoB) are more accurate in estimating lipid-related cardiovascular disease risk.	density lipoprotein cholesterol	4-35	component of oligomeric golgi complex 2	Homo sapiens	37-42	
27601888-10	2016	Predictors for better LDL-C attainment were younger age (beta=-0.228; P=0.032) and higher knowledge score (beta=-0.255; P=0.049), while predictors for high-density lipoprotein cholesterol attainment were male (beta=0.268; P=0.006), smoking (beta=-0.192; P=0.045), and higher knowledge score (beta=-0.195; P=0.039).	density lipoprotein cholesterol	156-187	component of oligomeric golgi complex 2	Homo sapiens	22-27	
24855368-1	2014	BACKGROUND: Statins modify correlations between apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) and apoB and non-high-density lipoprotein cholesterol (non-HDL-C); however, it is not known whether niacin-based therapies have similar effects.	density lipoprotein cholesterol	80-111	component of oligomeric golgi complex 2	Homo sapiens	113-118	
30918334-2	2019	We aimed to confirm that in a range of low-density lipoprotein cholesterol (LDL-c) levels (from <70 mg/dl to >=160 mg/dl), other lipid parameters, such as triglyceride (TG) level, non-high-density lipoprotein cholesterol (non-HDL-c) level, and the total cholesterol (TC)/HDL-c ratio, are still related to arterial stiffness, which is a recognized marker of atherosclerosis.	density lipoprotein cholesterol	43-74	component of oligomeric golgi complex 2	Homo sapiens	76-81	
29729963-1	2018	BACKGROUND AND AIMS: Non-high-density lipoprotein cholesterol (non-HDL-C) goals are defined as 30 mg/dL (0.78 mmol/L) higher than the respective low-density lipoprotein cholesterol (LDL-C) goals.	density lipoprotein cholesterol	30-61	component of oligomeric golgi complex 2	Homo sapiens	182-187	
28291866-1	2017	Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome.	density lipoprotein cholesterol	103-134	component of oligomeric golgi complex 2	Homo sapiens	136-141	
25957119-9	2015	Low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol levels declined over the 9-year period (P = 0.005 and P = 0.006, respectively), and the ratio of statin users increased markedly from 24% to 54% (P = 0.001).	density lipoprotein cholesterol	4-35	component of oligomeric golgi complex 2	Homo sapiens	37-42	
23255853-4	2012	Calculated and directly-measured low density lipoprotein cholesterol (LDL-C) values were highly correlated (r = 0.96); however, significant differences were observed between the directly-measured and calculated LDL-C concentrations.	density lipoprotein cholesterol	37-68	component of oligomeric golgi complex 2	Homo sapiens	70-75	
22284919-3	2012	RESULTS: We retrieved 207 questionnaires of patients aged 10.9 +- 4.2 years (mean +- SD) at diagnosis; 48% were boys, and the mean low-density lipoprotein cholesterol (LDL-C) level at diagnosis was 167 +- 51 mg/dL.	density lipoprotein cholesterol	135-166	component of oligomeric golgi complex 2	Homo sapiens	168-173	
19901173-10	2009	Low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol levels were associated with a paradoxical reduction in risk of stroke.	density lipoprotein cholesterol	4-35	component of oligomeric golgi complex 2	Homo sapiens	37-42	
21291811-9	2009	Changes in total and non-high-density lipoprotein cholesterol paralleled those for LDL-C.	density lipoprotein cholesterol	30-61	component of oligomeric golgi complex 2	Homo sapiens	83-88	
8252717-1	1993	Treatment of hyperthyroidism increased the mean Lp(a) concentrations by 60% (from 73 to 102 mg/L, P < 0.002); at the same time, low-density lipoprotein cholesterol (LDL-C) increased by 53% (from 2.6 to 3.7 mmol/L, P < 0.0001) and apolipoprotein B (apo B) by 35% (from 0.91 to 1.17 g/L, P < 0.0005).	density lipoprotein cholesterol	135-166	component of oligomeric golgi complex 2	Homo sapiens	168-173	
12661776-5	2003	At baseline, total cholesterol, low density lipoprotein cholesterol (LDL-C) and LDL-C/high density lipoprotein cholesterol (HDL-C) ratio were positively related to aortic stiffness (p < 0.001 for all).	density lipoprotein cholesterol	36-67	component of oligomeric golgi complex 2	Homo sapiens	69-74	
21291724-2	2008	Lipid treatment guidelines are established for low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C).	density lipoprotein cholesterol	51-82	component of oligomeric golgi complex 2	Homo sapiens	84-89	
24678100-6	2006	METHODS: In this post hoc analysis, Cox regression analysis was performed to study the relationship between on-treatment (pravastatin 5-20 mg/d) LDL-C level and CVE risk reduction using age, sex, smoking status, presence of diabetes mellitus and/or hypertension, history of cardiovascular disease (CVD), and high-density lipoprotein cholesterol level as adjustment factors.	density lipoprotein cholesterol	313-344	component of oligomeric golgi complex 2	Homo sapiens	145-150